Form 3 Aevi Genomic Medicine, Inc.

Initial statement of beneficial ownership of securities

Published: 2019-06-11 16:03:28
Submitted: 2019-06-11
Period Ending In: 2019-06-01
edgar.html PRIMARY DOCUMENT


>

SEC FORM 3

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
McInaw Michael

(Last) (First) (Middle)
C/O AEVI GENOMIC MEDICINE, INC.
435 DEVON PARK DRIVE, SUITE 715

(Street)
WAYNE PA 19087

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2019
3. Issuer Name and Ticker or Trading Symbol
Aevi Genomic Medicine, Inc. [ GNMX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Interim CFO
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 16,107 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 07/29/2026 Common Stock 6,500 5.77 D
Stock Option (right to buy) (2) 02/17/2027 Common Stock 1,500 4.91 D
Stock Option (right to buy) (3) 06/02/2027 Common Stock 5,000 1.24 D
Stock Option (right to buy) (4) 08/11/2027 Common Stock 5,000 1.32 D
Stock Option (right to buy) (5) 04/17/2028 Common Stock 26,250 1.55 D
Stock Option (right to buy) (6) 01/22/2028 Common Stock 6,500 1.52 D
Explanation of Responses:
1. One-Third of the option grant vested and became exercisable on each of July 29, 2017 and July 29, 2018 (2,166 options and 2,167 options, respectively), and the rest will vest and become exercisable on July 29, 2019, subject to the reporting person's continued service with the issuer.
2. One-third of the option grant vested and became exercisable on each of February 17, 2018 and February 17, 2019, and the rest will vest and become exercisable on February 17, 2020, subject to the reporting person's continued service with the issuer.
3. One-third of the option grant vested and became exercisable on each of June 2, 2018 and June 2, 2019 (rounded up to the nearest whole share of common stock), and the rest will vest and become exercisable on June 2, 2020, subject to the reporting person's continued service with the issuer.
4. One-third of the option grant vested and became exercisable on August 11, 2018 (rounded up to the nearest whole share of common stock), and the remaining will vest and become exercisable in one-third increments annually on the anniversary of the grant date, subject to the reporting person's continued service with the issuer.
5. One-third of the option grant vested and became exercisable on April 17, 2019, and the remaining will vest and become exercisable in one-third increments annually on the anniversary of the grant date, subject to the reporting person's continued service with the issuer.
6. The options vested and became exercisable on March 30, 2018.
Remarks:
/s/ Michael McInaw 06/11/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
1
edgar.xml PRIMARY DOCUMENT
Schema Version:
X0206
Document Type:
3
Period Of Report:
2019-06-01
No Securities Owned:
0

Issuer

Issuer Cik
0001138776
Issuer Name
Aevi Genomic Medicine, Inc.
Issuer Trading Symbol
GNMX

Reporting Owner

Reporting Owner Id

Rpt Owner Cik
0001778747
Rpt Owner Name
McInaw Michael

Reporting Owner Address

Rpt Owner Street1
C/O AEVI GENOMIC MEDICINE, INC.
Rpt Owner Street2
435 DEVON PARK DRIVE, SUITE 715
Rpt Owner City
WAYNE
Rpt Owner State
PA
Rpt Owner Zip Code
19087

Reporting Owner Relationship

Is Director
0
Is Officer
1
Is Ten Percent Owner
0
Is Other
0
Officer Title
Interim CFO

Non Derivative Holding

Security Title
Common Stock
Shares Owned Following Transaction
16107

Ownership Nature

Direct Or Indirect Ownership
D

Derivative Holding

Security Title
Stock Option (right to buy)
Conversion Or Exercise Price
5.77
@attributes Id
F1
Expiration Date
2026-07-29

Underlying Security

Underlying Security Title
Common Stock
Underlying Security Shares
6500

Ownership Nature

Direct Or Indirect Ownership
D
Security Title
Stock Option (right to buy)
Conversion Or Exercise Price
4.91
@attributes Id
F2
Expiration Date
2027-02-17

Underlying Security

Underlying Security Title
Common Stock
Underlying Security Shares
1500

Ownership Nature

Direct Or Indirect Ownership
D
Security Title
Stock Option (right to buy)
Conversion Or Exercise Price
1.24
@attributes Id
F3
Expiration Date
2027-06-02

Underlying Security

Underlying Security Title
Common Stock
Underlying Security Shares
5000

Ownership Nature

Direct Or Indirect Ownership
D
Security Title
Stock Option (right to buy)
Conversion Or Exercise Price
1.32
@attributes Id
F4
Expiration Date
2027-08-11

Underlying Security

Underlying Security Title
Common Stock
Underlying Security Shares
5000

Ownership Nature

Direct Or Indirect Ownership
D
Security Title
Stock Option (right to buy)
Conversion Or Exercise Price
1.55
@attributes Id
F5
Expiration Date
2028-04-17

Underlying Security

Underlying Security Title
Common Stock
Underlying Security Shares
26250

Ownership Nature

Direct Or Indirect Ownership
D
Security Title
Stock Option (right to buy)
Conversion Or Exercise Price
1.52
@attributes Id
F6
Expiration Date
2028-01-22

Underlying Security

Underlying Security Title
Common Stock
Underlying Security Shares
6500

Ownership Nature

Direct Or Indirect Ownership
D

Footnote

0
One-Third of the option grant vested and became exercisable on each of July 29, 2017 and July 29, 2018 (2,166 options and 2,167 options, respectively), and the rest will vest and become exercisable on July 29, 2019, subject to the reporting person's continued service with the issuer.
1
One-third of the option grant vested and became exercisable on each of February 17, 2018 and February 17, 2019, and the rest will vest and become exercisable on February 17, 2020, subject to the reporting person's continued service with the issuer.
2
One-third of the option grant vested and became exercisable on each of June 2, 2018 and June 2, 2019 (rounded up to the nearest whole share of common stock), and the rest will vest and become exercisable on June 2, 2020, subject to the reporting person's continued service with the issuer.
3
One-third of the option grant vested and became exercisable on August 11, 2018 (rounded up to the nearest whole share of common stock), and the remaining will vest and become exercisable in one-third increments annually on the anniversary of the grant date, subject to the reporting person's continued service with the issuer.
4
One-third of the option grant vested and became exercisable on April 17, 2019, and the remaining will vest and become exercisable in one-third increments annually on the anniversary of the grant date, subject to the reporting person's continued service with the issuer.
5
The options vested and became exercisable on March 30, 2018.

Owner Signature

Signature Name
/s/ Michael McInaw
Signature Date
2019-06-11
poamcinaw.htm POA


> ENT> EX-24 2 poamcinaw.htm POA
                                POWER OF ATTORNEY



 KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes

and appoints Michael Cola with full power of substitution or

revocation, the undersigned's true and lawful attorney-in-fact to:



 (1)  prepare and execute on the undersigned's behalf and submit to the

U.S. Securities Exchange Commission (the "SEC") a Form ID, including amendments

thereto,and any other documents necessary or appropriate to obtain codes

and passwords enabling the undersigned to make electronic filings with the

SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934

or any rule or regulation of the SEC;



 (2)  execute for and on behalf of the undersigned, in the undersigned's

capacity as an officer, director and/or trustee of Aevi Genomic Medicine, Inc.

(the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the

Securities Exchange Act of 1934, as amended, and the rules thereunder;



 (3)  do and perform any and all acts for and on behalf of the

undersigned which may be necessary or desirable to complete and execute

any such Form 3, 4 or 5, complete and execute any amendment or amendments

thereto and timely file such forms with the SEC and any stock exchange

or similar authority; and



 (4)  take any other action of any type whatsoever in connection

with the foregoing which, in the opinion of such attorney-in-fact, may be of

benefit to, in the best interest of, or legally required by, the undersigned,

it being understood that the documents executed by such attorney-in-fact

on behalf of the undersigned pursuant to this Power of Attorney shall be in

such form and shall contain such terms and conditions as such attorney-in-fact

may approve in such attorney-in-fact's discretion.



      The undersigned hereby grants to such attorney-in-fact full power

and authority to do and perform any and every act and thing whatsoever

requisite, necessary or proper to be done in the exercise of any of the

rights and powers herein granted, as fully to all intents and purposes as the

undersigned might or could do if personally present, with full power of

substitution or revocation, hereby ratifying and confirming all that such

attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall

lawfully do or cause to be done by virtue of this Power of Attorney and the

rights and powers herein granted.  The undersigned acknowledges that the

foregoing attorneys-in-fact, in serving in such capacity at the request of

the undersigned, is not assuming, nor is the Company assuming, any of the

undersigned's responsibilities to comply with Section 16 of the Securities

Exchange Act of 1934, as amended.



 This power of attorney shall remain in full force and effect until

until the undersigned is no longer required to file Forms 3, 4, and 5 with

respect to the undersigned's holdings of and transactions in securities issued

by the Company, unless earlier revoked by the undersigned in a signed writing

delivered to the foregoing attorneys-in-fact. This Power of Attorney revokes

all prior Powers of Attorney given by the undersigned with respect to the

matters addressed in (1) through (4) above.



 IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney

to be executed as of the June 4, 2019.







     By:  /s/ Michael McInaw

     Name: Michael McInaw





Additional Files
FileSequenceDescriptionTypeSize
0001192482-19-000278.txt   Complete submission text file   15857
$GNMX

© 2019 SEC.report
SEC CFR Title 17 of the Code of Federal Regulations.